Application of Proteomics in Alzheimer’s Disease: A Mini Review
-
Published:2023-09-11
Issue:5
Volume:19
Page:317-330
-
ISSN:1675-8544
-
Container-title:SEPTEMBER 2023
-
language:en
-
Short-container-title:MJMHS
Author:
Sukumaran Pariveena,Bahardin Ainun Aida,Abdul Razak Luqmanul Hakim,Senik Mohd Harizal
Abstract
Alzheimer’s disease (AD) is classified as one of neurodegenerative disease caused by neuronal death. It is characterized as memory impairment, including the inability to produce new memories. Since AD has low treatment effectiveness, proteomics research opens possibilities for advancement. Proteomics is the study of proteomes produced by the disease-bearing host to identify and understand diseases. In this case, to investigate the use of protein as a reliable molecular entity and their involvement in AD. Therefore, this review focused on three main applications of proteomics; the potential use of proteomics as a diagnostic tool for AD, the use of proteomics to assess the treatment progression of AD and the advancement in AD research. The review discussed three research areas utilizing the proteomics approach: ageing, behavioural, and demographic research of AD populations. Proteomic approaches have also been shown to be effective to discover the biomarkers for infectious diseases, cancers, heart diseases, and neurological disorders. Although much work remained to be done, the proteomics approach is an interesting method to be carried out in detecting AD at an earlier stage and will be very useful for AD treatment and management in the future.
Publisher
Universiti Putra Malaysia
Reference108 articles.
1. 1. Moujalled, D., Strasser, A., & Liddell, J. R. (2021). Molecular mechanisms of cell death in neurological diseases. Cell Death & Differentiation 2021 28:7, 28(7), 2029–2044. doi:10.1038/s41418-021-00814-y 2. 2. Pang, S. Y. Y., Teo, K. C., Hsu, J. S., Chang, R. S. K., Li, M., Sham, P. C., & Ho, S. L. (2017). The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: A review. Translational Neurodegeneration, 6(1), 1–11. doi:10.1186/S40035-017-0098-0/TABLES/3 3. 3. Nuri, T. H. M., Hong, Y. H., Ming, L. C., Joffry, S. M., Othman, M. F., & Neoh, C. F. (2017). Knowledge on Alzheimer’s Disease among Public Hospitals and Health Clinics Pharmacists in the State of Selangor, Malaysia. Frontiers in Pharmacology, 8(OCT), 739. doi:10.3389/FPHAR.2017.00739 4. 4. Magalingam, K. B., Radhakrishnan, A., Ping, N. S., & Haleagrahara, N. (2018). Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease. BioMed Research International, 2018. doi:10.1155/2018/3740461 5. 5. Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., Awasthi, A., Barker-Collo, S. L., Baune, B. T., Béjot, Y., Belachew, A. B., Bennett, D. A., Biadgo, B., Bijani, A., Bin Sayeed, M. S., … Murray, C. J. L. (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(1), 88–106. doi:10.1016/S1474-4422(18)30403-4
|
|